ABSTRACT
INTRODUCTION
Adoptive transfer of donor-derived lymphocytes can induce durable remissions in Ͼ80% of marrow allograft recipients relapsing with chronic myelogenous leukemia, and in 25 to 30% of patients relapsing with acute myelogenous leukemia (AML) or myeloma (1, 2) . In patients treated for chronic myelogenous leukemia, this antileukemic activity has been ascribed to allospecific T cells reacting against clonogenic Ph ϩ hematopoietic precursors (3, 4) . Indeed, the transfer of clones of such cells has induced remissions in isolated cases (3) . Unfortunately, minor alloantigen-specific T cells can also induce graft-versushost disease (5) . An alternative strategy for adoptive therapy would be to use T cells specific for antigens differentially expressed by leukemic cells, such as T-cell receptor (TCR) and immunoglobulin idiotypes specific to leukemic clones (6, 7) , the protein products of fusion genes resulting from leukemia-specific translocations such as bcr/abl (8) , or oncofetal proteins differentially expressed by leukemic blasts. Two oncofetal proteins [the Wilms tumor gene product, WT1 (9, 10, 11) , and proteinase 3 (12) ] have recently been proposed for evaluation.
WT1, a gene mutated in Wilms tumor, encodes a zinc finger transcription factor that binds and represses promoters of several important growth factor genes (13, 14) . Expression of WT1 is high during fetal development of the genitourinary system. Postnatally, WT1 can be detected only at low levels in kidneys, splenic capsule, Sertoli cells of the testis, and granulosa cells of the ovary (14) , as well as in normal CD34
ϩ hematopoietic progenitors (15, 16) . In contrast, WT1 is overexpressed in a high proportion of patients with acute lymphoblastic leukemia, AML, myelodysplastic syndrome, and chronic myelogenous leukemia (17) , and has been specifically correlated with a poor outcome in patients with AML and myelodysplastic syndrome (18, 19) . WT1 is also highly expressed in several solid tumors (20, 21, 22, 23) .
Recently, immunogenic peptides of WT1 with high affinity for HLA-A2402 and HLA-A0201 have been identified. T-cell clones (9, 10) specific for these peptides have been isolated and expanded from single donors that specifically lysed WT1 ϩ
HLA-A2402
ϩ or WT1 ϩ HLA-A0201 ϩ leukemia cell lines in vitro (9, 10) and inhibited the growth of lung cancer xenografts in nude mice in vivo (24) . Recently, Gaiger et al. (25) and Eliseeva et al. (26) detected antibodies to WT1 in up to 29% of patients with AML. Scheibenbogen et al. (27) also recorded low but detectable frequencies of WT1-peptide-specific IFN␥-secreting T cells in the blood of Ͼ30% of patients with AML but not in normal donors. However, Rezvani et al. (28) detected IFN␥ mRNA in T cells stimulated with WT1-peptide in 10 of 18 healthy individuals and WT1-peptide-HLA-A0201-tetramerbinding T cells in a small subset of these individuals. Recently, Gao et al. (11) have also generated alloreactive T cells from
HLA-A0201
Ϫ donors specific for HLA-A0201 ϩ cells expressing WT1, which could lyse WT1
ϩ HLA-A0201 ϩ leukemic cells and deplete clonogenic cells capable of transferring leukemia in nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice (29) . However, to date, no study has evaluated the capacity of HLA-binding peptides derived from this potentially tolerogenic "self" protein to stimulate the generation of WT1-peptide-specific HLA-restricted T cells from random HLA-A0201-or HLA-A2402-bearing normal donors in comparison with the responses to known immunogenic peptides derived from viral proteins. Furthermore, the in vivo leukemocidal activity of the WT1-specific T cells generated from normal individuals has not been evaluated.
In this study, we demonstrate that HLA-restricted CD8 ϩ cytotoxic T-cell lines that are specific for WT1 immunogenic peptides can be regularly generated in vitro from HLA-A0201 ϩ and HLA-A2402 ϩ normal human donors after sensitization with autologous peptide-loaded cytokine-activated monocytes (CAMs) or EBV-transformed B cells (EBV-BLCLs). Strikingly, the frequencies of WT1-peptide-specific T cells, generated in response to peptide-loaded EBV-BLCLs, were similar to those generated against highly immunogenic EBV peptides. These T cells specifically lysed WT1 ϩ leukemias and selected WT1 EBV-BLCLs were generated by infecting peripheral blood mononuclear cells (PBMCs) with the EBV isolate B95.8, as described previously (31) . To generate CAMs, we cultured PBMC-derived plastic-adherent monocytes in RPMI 1640, containing 5% human AB serum (HS; Gemini, Calabasas, CA). Interleukin (IL)-4(1,000 IU/mL) and granulocyte-macrophage colony-stimulating factor (GM-CSF, 1,000 IU/mL; both from Sigma, St. Louis, MO) were added on days 0, 2, 4, and 6 of culture. Beginning on day 6, tumor necrosis factor ␣ (10 ng/mL; Sigma) was added to the medium. CAMs harvested at day 9 were used for T-cell sensitizations.
To prepare peptide-loaded antigen-presenting cells (APCs), we incubated 1 to 2 ϫ 10 6 cells/mL CAMs or EBV-BLCLs from the same donor for 3 hours with a 50 g/mL of one of the synthetic WT1 nonapeptides in serum-free medium; we then washed and irradiated the cells before sensitization of autologous T cells.
T-cell-enriched fractions of PBMCs were obtained by depletion of monocytes by adhesion, followed by immunoadsorption of cells binding anti-CD56/CD16 monoclonal antibodies (Immunotech, Marseille, France) with antimouse IgGcoated immunomagnetic beads (Nexell Therapeutics, Irvine, CA). These cells were then stimulated with WT1-negative EBVBLCLs or CAMs (EBV-CTLs or CAM-CTLs) or WT1-peptideloaded autologous EBV-BLCLs or CAMs (WT1/EBV-CTLs or WT1/CAM-CTLs) at a 20:1 responder-to-stimulator (R:S) ratio and cultured in Yssel's medium, containing 5% HS(YH5; Gemini), supplemented every 2 to 3 days with 10 to 30 units/mL IL-2 (Collaborative Biomedical Products, Bedford, MA) beginning from day 7 and restimulated weekly with the same APCs at a 4:1 R:S ratio.
Quantitation of WT1-Specific T cells. T cells recognizing HLA-A0201-binding WT1-peptides were quantitated by fluorescence-activated cell sorting (FACS) analysis of CD8 ϩ CTLs binding RMF/HLA-A0201-or SLG/HLA-A0201-PE-labeled tetramers. EBV-specific T cells were also quantitated by using EBNA3C/A0201, LMP1/A0201, LMP2/ A0201, BZLF1/A0201, BMLF1/A0201 PE-labeled tetramers. Tetramers were generated in the MSKCC Tetramer Core Facility, as described previously (32) .
T cells producing intracellular IFN␥ in response to secondary stimulation with peptides were quantitated as described previously (33) .
The WT1-peptide-and EBV-specific cytotoxic activity of sensitized T cells was measured with a standard 51 Cr-release assay, as previously described (31) .
Expression of WT1 protein by target cells was measured by FACS analysis after permeabilization and staining with mouse antihuman-WT1 (Neomarkers, Fremont, CA) and goat-antimouse FITC-conjugated antibodies (Becton Dickinson, San Jose, CA). Surface expression of HLA-class I and II was assessed by FACS analysis with FITC-labeled monoclonal antibodies (Becton Dickinson). HLA typing was performed as previously described (34) .
Colony-Inhibiting Activity of WT1-Specific CTLs.
Isolated CD34
ϩ cells (5 ϫ 10 2 ), preincubated for 4 hours at 37°C 5% CO 2 with or without 2.5 ϫ 10 4 of WT1/EBV-CTLs or EBV-CTLs, were cocultured with the same effector cells in triplicate in 35- (31, 36, 37) . Briefly, up to four separate human tumor xenografts were established in 4-to-6-week-old male NOD-SCID mice (Taconic Farms, Germantown, NJ) by subcutaneous injection of 5 ϫ 10 6 cells of each tumor type suspended in Matrigel into the thighs or shoulders. After the development of measurable tumors, specified test and control groups of mice (n ϭ 5 per group) were treated intravenously with WT1/EBV-CTLs or EBV-CTLs. All of the mice were also treated with 2,000 IU of rhIL-2 three times a week beginning from the day of the CTL injection.
Mice were monitored daily, and tumor volumes were measured weekly, as described previously (31) . At specified intervals after the T-cell infusion, mice were sacrificed, and tumors and organs were examined for WT1 ϩ tumor cells and infiltrating CD3 ϩ T cells with standard immunohistochemical techniques. In vivo Monitoring of T cells After Adoptive Transfer. WT1/EBV-CTLs or EBV-CTLs were transduced with a modified retroviral vector encoding a herpes simplex virus thymidine kinase/green fluorescence protein (HSV-TK/GFP)-fusion protein containing CpG-reduced HSV-TK cDNA, as described previously (31, 38, 39) . Transduced T cells expressing GFP were isolated with a MoFlo FACS Sorter (Cytonation, Fort Collins, CO) and were expanded in the presence of OKT3 antibodies (Ortho Biotech, Raritan, NJ), autologous irradiated PBMCs, and autologous irradiated RMF-loaded (RMF-BLCL) or unloaded EBV-BLCL. Before adoptive transfer, the transduced T cells were tested for binding to RMF and EBV-peptide/ tetramer and for cytotoxicity against WT1 ϩ and EBV ϩ targets. HSV-TK expression was evaluated as described previously (40) .
For in vivo imaging of antigen-specific migration and targeting of EBV-and WT1-reactive T cells, 28 All of the animals were treated with 2000 units of IL-2 per mouse, three times a week, throughout the course of the experiment from the day of T-cell injection. Animals were sacrificed after imaging. Tumors and tissue samples were assessed for radiotracer accumulation, and selected single-cell suspensions thereof were analyzed by FACS for infiltration with enhanced-GFP (eGFP)-expressing T cells.
Statistical Analysis. A permutation test was used to determine differences in tumor volume between groups in the mouse studies. The test statistic was based on the average of differences in tumor volume between groups stratified over time. Kendall's Tau statistic was used to assess the level of monotone association between the proportion of target cells that expressed WT1 and cytolysis by WT1-peptide-sensitized T cells. RMF/HLA-A0201-tetramer-binding cells detected in EBV-CTLs or CAM-CTLs ranged from 0.01 to 0.19%. In contrast, significant percentages of RMF/HLA-A0201-tetramerbinding T cells were detected in cultures sensitized with RMFBLCLs (RMF/EBV-CTLs) or RMF-CAMs (RMF/CAM-CTLs), ranging between 1 and 32% and 0.8 and 5%, respectively. In the donors tested for responses to both RMF and SLG, the percentages of T cells in the SLG-stimulated cultures (SLG/EBV-CTLs or SLG/CAM-CTLs) binding SLG/HLA-A0201-tetramers were similar to those in RMF/EBV-CTLs or RMF/CAM-CTLs binding RMF/HLA-A0201-tetramers.
RESULTS

WT1-Specific T-Cell Responses After
Strikingly, for each of 13 donors tested, the percentages of RMF-or SLG/HLA-A0201-tetramer-binding T cells detected in WT1/EBV-CTLs were equivalent to the frequencies of the EBV-specific T cells detected in the same cultures binding EBNA3C-, BZLF-1-, BMLF-1-, or LMP-2-EBVpeptide/HLA-A0201 tetramers ( Fig. 1A and B) . Furthermore, the percentages of EBV-peptide-reactive T cells detected in WT1/EBV-CTLs did not differ from those detected in EBVCTLs. Moreover, the levels of tetramer-binding exhibited by WT1/EBV-CTLs, when exposed to either RMF/HLA-A0201-or EBNA3C/HLA-A0201-tetramers, were also similar, as reflected by mean fluorescence of the positive cells (Fig. 1C) . The percentages of WT1/EBV-CTLs or EBV-CTLs that bound HLA-A0201-LMP1-tetramers were less than 1% in 11 of 13 donors tested, a finding consistent with the known poor immunogenicity of LMP1 peptides.
We also compared yields of WT1-reactive T cells in cultures sensitized with either RMF-BLCLs or RMF-CAMs. At each week tested, the yield of CD8 ϩ T cells binding RMF/HLA-A0201-tetramers was significantly greater in WT1/EBV-CTLs (Fig. 1D) .
CTLs from 7 of the 13 HLA-A0201 ϩ donors, contemporaneously sensitized for 35 to 42 days with RMF-BLCLs, RMFCAMs, and EBV-BLCLs, were also tested for their content of T cells that generated IFN␥ in response to restimulation with autologous RMF-loaded PBMCs and for their cytotoxic activity EBV-CTLs contained negligible levels of tetramer-binding or IFN␥-producing RMF-specific T cells and lysed only autologous EBV-BLCLs (Fig. 2) Ϫ HLA-A0201 ϩ AML (Fig. 2C ). As expected, RMF/EBV-CTLs lysed autologous EBV-BLCLs, whereas RMF/CAM-CTLs did not. CAM/CTL did not bind WT1-peptide-/HLA-A0201-tetramers (Fig. 1A) . Cell yields of these T-cell cultures, however, were insufficient to permit analysis of cytokine generation or cytotoxic activity.
Five donors expressing HLA-A2402 were tested for responses to a newly identified HLA-A2402--binding WT1-peptide, RVP, when loaded on autologous CAMs (n ϭ 3; RVPCAMs) and/or EBV-BLCLs (RVP-BLCLs; n ϭ 5; Table 1 ). Unfortunately, stable RVP/HLA-A2402 tetramers could not be generated. However, the RVP-peptide-sensitized T cells generated from each donor specifically lysed RVP-loaded autologous PHA blasts as well as unmodified HLA-A2402 ϩ WT1 ϩ leukemic cells. Furthermore, T cells from each of two donors, coexpressing HLA-A2402 and HLA-A0201 sensitized with RVPloaded-APCs, exhibited equal or greater cytotoxicity against Table 1) .
Sensitivity of Normal Hematopoietic Cells, Leukemic Blasts, and Solid Tumor Cells to WT1-Peptide-Specific CTLs. The proportion of HLA-A0201 ϩ CD34 ϩ PBSCs and cord blood mononuclear cells lysed by the WT1/CAM-CTLs and WT1/EBV-CTLs was extremely low, and similar to the proportion of WT1 Ϫ PHA blasts lysed by these cells (Fig. 3A) . In contrast, these T cells exhibited a significant cytolytic activity against 6 of 9 leukemias and 4 of 11 solid tumor cell lines tested. The level of cytotoxicity observed was correlated with the percentage of cells in the target cell population that expressed WT1 (Kendall's Tau statistic ϭ 0.57; P Ͻ 0.001; Fig. 3B, top  panel) .
In normal or malignant target cell populations containing either high or low proportions of WT1 ϩ cells, WT1 ϩ cells exhibited a uniformly high-intensity fluorescence that was easily distinguishable from negative cell populations (Fig. 3B,  bottom panel) . To ascertain the limits of the cytotoxicity assay for discriminating activity against these WT1 ϩ cells, we assessed the cytotoxic activity of RMF/EBV-CTLs from three donors against a WT1
ϩ HLA-A0201 ϩ B-ALL serially diluted with WT1 Ϫ CD34 ϩ PBSCs (Fig. 3C) . Again, cytolysis was significantly correlated with the percentage of WT1 ϩ cells in the target pool (Kendall's Tau statistic ϭ 0.56, P Ͻ 0.001). However, at concentrations of WT1 ϩ cells Ͻ20%, cytotoxicity could not be distinguished from that against WT1 Ϫ controls. Because clonogenic progenitors could be included in the small fraction of WT1 ϩ CD34 ϩ PBSCs, we also compared RMF/EBV-CTLs and EBV-CTLs for their potential to inhibit the growth of hematopoietic progenitors from CD34
ϩ PBSCs. The growth of CFU-GM, burst-forming unit erythroid, and CFU-mix was not affected by either of the T-cell populations when compared with the growth of these progenitors in the absence of CTLs (Fig. 3D) .
In vivo Effects of WT1/EBV-Specific T Cells. In initial experiments, adoptive transfer of RMF/EBV-CTLs or SLG/
EBV-CTLs inhibited growth of WT1
ϩ HLA-A0201 ϩ T-ALL xenografts to an equivalent degree ( Fig. 4A ; P Ͻ 0.01). Single infusions of RMF/EBV-CTLs also induced regressions of fresh HLA-A0201 ϩ WT1 ϩ AML xenografts(P Ͻ 0.01; Fig. 4B ). When regrowth of the leukemic xenografts was detected at week 9, a second infusion of these T cells induced a complete regression of the leukemia in each of the five mice treated.
To further assess the target specificity of T cells in vivo, RMF/EBV-CTLs were adoptively transferred into NOD-SCID mice simultaneously bearing subcutaneous xenografts of human WT1
ϩ HLA-A0201 ϩ B-ALL and WT1 Ϫ HLA-A0201 ϩ B-ALL (63% versus 3% WT1 ϩ cells). Sequential intravenous infusions of RMF/EBV-CTLs significantly inhibited the growth of WT1 ϩ leukemia (P Ͻ 0.01; Fig. 4C, top panel) . In contrast, the growth of WT1 -leukemia (Fig. 4D, top panel) was not affected. EBVCTLs had no effect on the growth of either WT1 ϩ or WT1 Ϫ leukemic xenografts ( Fig. 4C and D, top panel) . Immunohistopathologic analyses of tumors harvested from mice treated with RMF/EBV-CTLs also demonstrated infiltration of T cells and necrosis in the WT1 ϩ leukemic xenograft (Fig. 4C, bottom  panel) . In contrast, the WT1 Ϫ leukemic xenografts from the same animals exhibited viable leukemic cells without evidence of T-cell infiltration or necrosis (Fig. 4, D, bottom panel) . Neither the WT1 ϩ nor the WT1 Ϫ leukemic xenografts exhibited T-cell infiltration or evidence of necrosis in mice treated with EBV-CTLs or with IL-2 alone (data not shown).
In vivo Imaging of RMF/EBV CTLs. To evaluate the in vivo distribution of the WT1/EBV-CTLs in xenografted mice, RMF-sensitized WT1/EBV-CTLs and EBV-CTLs that were contemporaneously expanded from the same donor and transduced with the HSV-TK/eGFP vector were then sorted by FACS to 98 and 95% purity, respectively. The sorted WT1/ EBV-TG-CTLs contained 3.1% of RMF/HLA-A0201-tetramer ϩ T cells compared with Ͻ0.1% in sorted EBV-TG-CTLs. WT1/ EBV-TG-CTLs lysed autologous RMF-PHA blasts and the HLA-A0201 ϩ WT1 ϩ leukemia. EBV-TG-CTLs did not lyse these targets. The cumulative proportions of T cells binding HLA-A0201-and HLA-B0701-tetramers that contained peptides of EBNA3C, BZLF1, BMLF1, and LMP2 were 50 and 52% in the WT1/EBV-TG-CTLs and EBV-TG-CTLs, respectively. These cells exhibited comparable HLA-A0201-restricted EBVspecific cytotoxicity (data not shown).
The K1 accumulation rate of the HSV-TK-substrate FIAU that characterized the HSV-TK-expression in sorted GFP ϩ T cells, measured by an in vitro radiotracer accumulation assay, was 0.234 mL/g/min and 0.192 mL/g/min for WT1/EBV-TGCTLs and EBV-TG-CTLs, respectively, FIAU-to-thymidine ratios were 0.0933 and 0.11, respectively, which satisfied the in vivo imaging criteria (38) .
Initially, we wanted to compare the ability of T cells in the WT1/EBV-TG-CTLs and EBV-TG-CTLs to migrate to WT1 ϩ or EBV ϩ tumors expressing the HLA-A0201 restricting allele. Scintigraphic images (Fig. 5A) [ 131 I]FIAU in the autologous EBV-BLCL tumor (Fig. 5A, T2 ) and allogeneic HLA-A0201 ϩ EBV-BLCL tumor (Fig. 5A, T3 ) in mice treated with either WT1/EBV-TG-CTLs or EBV-TGCTLs. In contrast, the WT1 ϩ HLA-A0201 ϩ B-ALL tumor (Fig.  5A, T1 ) was visualized only in the animals treated with WT1/ EBV-TG-CTLs. No signal was observed in the HLA-A0201 ϩ
WT1
-leukemia tumor (Fig. 5A, T4) in any of the treated groups of animals. Furthermore, none of these tumors were visualized after [
131 I]FIAU infusion in the animals treated with IL-2 alone (control).
Images obtained 8 days after T-cell injections (24 hours after a second dose of [
131 I]FIAU) demonstrated additional radiotracer accumulation in the HLA-A0201 ϩ EBV-BLCL xenografts (Fig. 5A, T2 and T3) . Increased signal was also seen in the WT1 ϩ B-ALL (Fig. 5A, T1 ) in animals treated with WT1/ EBV-TG-CTLs but not in the animals treated with EBV-TGCTLs. Again, [
131 I]FIAU was not detected in the WT1 Ϫ leukemia. Images of mice treated with either WT1/EBV-TG or EBV-TG-CTLs also demonstrated signal in the spleen both at day 2 and at day 8 after the CTL injection. Direct measurements of radioactivity in tissue samples (Fig. 5B) (Fig. 5B, T2 and T3 ) in animals treated with either of the T-cell populations, and a selective accumulation of radiolabel in 
ϩ leukemia (Fig. 5B, T1 ) in the animals treated with WT1/EBV-TG-CTLs. Only low levels of the radioisotope, comparable with those in stomach, colon, and muscles, were retained in the WT1 Ϫ leukemia. FACS analysis of the tumor cell suspensions also demonstrated infiltration of T1, T2, and T3 tumors with GFP ϩ T cells in the animals treated with WT1/ EBV-TG-CTLs, whereas only the EBV ϩ tumors T2 and T3 contained a proportion of GFP ϩ T cells in the animals treated with EBV-TG-CTLs (Fig. 5C) .
In subsequent experiments, we used positron emission tomography (PET) imaging to examine with greater precision the migration of TK/eGFP-transduced T cells into tumor xenografts varying only in their expression of WT1 or the restricting HLA-A0201. The axial cross-sectional PET images (Fig. 5D) , through tumors in the shoulders (Fig. 5D, T1 and T2) and thighs (Fig. 5D, T3 and T4), were obtained on days 1 and 8 after the injection of WT1/EBV-TG-CTLs or EBV-TG-CTLs into NOD-SCID mice, bearing a WT1 ϩ HLA-A0201 ϩ rhabdomyosarcoma (Fig. 5D, T1) , a WT1
ϩ HLA-A0201 ϩ B-ALL (Fig. 5D, T2) , a WT1
ϩ HLA-A0201 Ϫ rhabdomyosarcoma (Fig. 5D, T3) , and a WT1
Ϫ HLA-A0201 ϩ B-ALL (Fig. 5D, T4) . [ 18 F]FEAU was accumulated in the WT1 ϩ HLA-A0201 ϩ tumors (Fig. 5D , T1 and T2) only in the animals treated with WT1/EBV-TG-CTLs. Accumulation of [
18 F]-FEAU was greater in the WT1 ϩ HLA-A0201 ϩ B-ALL(T2). By FACS analysis, the proportion of T1 and T2 cells that expressed surface HLA-class-I was the same (99%). However, more T2 cells expressed WT1 (60% versus 44%), and they were more sensitive to RMF/EBV-CTLmediated killing in vitro [60% versus 25% at an effector-totarget (E:T) ratio of 50:1]. This characteristic might explain the differences observed in T-cell accumulations.
WT1/EBV-TG-CTLs did not accumulate in tumor T3. This rhabdomyosarcoma contained a high proportion of WT ϩ cells (73%) and was genotypically HLA-A0201 ϩ . However, it did not express the HLA-A0201 allele on the cell surface (1% HLAclass-I ϩ cells) and was not lysed by the HLA-A0201-restricted RMF/EBV-TG-CTLs in vitro.
As expected, WT1/EBV-TG-CTLs, also, did not accumulate in the WT1
Ϫ HLA-A0201 ϩ B-ALL (Fig. 5D, T4 ). These results, thus, demonstrate a requirement for the coexpression of the specific antigen and the T-cell-restricting HLA allele on tumor cells for T-cell targeting and tumor-selective accumulation in vivo.
DISCUSSION
Differential expression of WT1 in most leukemias (17, 18, 19) and several solid tumors (20, 21, 22, 23) 
HLA-A2402
ϩ leukemia indicates that the RVP peptide is naturally presented after intracellular processing of WT1 protein.
The in vitro generation of T cells for adoptive cell therapy can often be thwarted by limited or inconsistent availability of donor-derived APCs, required for repeated in vitro restimulations of T cells during selection and expansion of antigenspecific CTL. EBV-BLCLs have advantages as APCs because they can be grown indefinitely and can express those determinants essential for antigen presentation. Indeed, transformation by EBV leads to enhanced APC function (through the upregulation of the peptide transporters TAP-1 and TAP-2) as well as to enhanced expression of MHC class I (41). EBV-BLCLs, transduced to express cytomegalovirus pp65, are highly effective in inducing cytomegalovirus pp65-specific T cells at levels equal to, or exceeding, those cogenerated against peptides of immunodominant EBV antigens such as EBNA-3 (42). However, from prior reports, it was unclear whether EBV-BLCLs, loaded with immunogenic peptides that were derived from a self antigen such as WT1 protein, would concomitantly elicit a significant WT1-specific T-cell response. Indeed, we expected that responses to WT1 peptides might be diluted out by responses to dominant EBV epitopes. Strikingly, however, in cultures sensitized with peptide-loaded autologous EBVBLCLs, the percentages of T cells specific for two different HLA-A0201-binding WT1 epitopes, RMF and SLG, were comparable with or exceeded those detected in populations of the same T cells contemporaneously sensitized with peptide-loaded CAMs. Furthermore, the total yield of WT1-peptide-specific T cells was consistently higher in cultures sensitized with the WT1-peptide-loaded EBV-BLCL.
It has been speculated that, because WT1 is a self protein, T-cell responses to WT1 peptides would be low and T cells, responding to self antigens, are subject to early deletion in the thymus and, if exported, are suppressed by regulatory T cells in normal individuals (43, 44) . For these reasons, we expected that the frequencies of WT1-specific T cells in cultures sensitized with peptide-loaded EBV-BLCLs would be low, and markedly lower than those generated against immunodominant EBV antigens. However, in the T cells sensitized with WT1-peptideloaded EBV-BLCL, the proportions of RMF-and SLG-HLA-A0201-tetramer-binding T cells were actually equal to those in T cells that bound tetramers of HLA-A0201 and immunogenic peptides of EBV. Thus, although the cumulative response to the spectrum of EBV antigens detected in the T-cell lines was much greater, responses to the WT1 peptide were surprisingly comparable with those generated against individual viral epitopes known to be highly immunogenic.
The T cells generated from HLA-A0201 ϩ and HLA-A2402 ϩ donors, sensitized with RMF and SLG(HLA-A0201) or RVP(HLA-A2402), were specifically cytotoxic for primary AML, B-ALL, and T-ALL, and leukemic cell lines, as well as for solid tumor cells expressing WT1 and their restricting HLA allele. In our studies, there was a significant correlation between the proportion of WT1 ϩ cells detected in each target population and the proportion of cells in that population lysed by the WT1-peptide-specific T cells. However, the mean fluorescence intensity of WT1 in the WT1 ϩ cells was strikingly high and very similar within each of the target cell populations. Because detection of WT1 in target cells necessitated permeabilization and fixation, we could not determine whether the WT1 ϩ cells that were detected in high proportions in tumor cell fractions resembled those in the small fraction of WT1 ϩ cells detected in cord blood or isolated CD34 ϩ cells, in their sensitivity to WT1-peptide-specific cytotoxic T cells. Inoue et al. (45) have reported that the concentration of WT1 RNA detected in isolated populations of normal CD34 ϩ marrow cells is 10-to 100-fold lower than that detected in populations of leukemic blasts. On the basis of these data and similar data from Gao et al. (11) , who measured WT1 RNA and protein in CD34 ϩ cell fractions, it could be hypothesized that normal CD34 ϩ cells express less WT1 and are, therefore, less susceptible to lysis by WT1-peptide-specific T cells. However, when Hosen et al. (46) subsequently measured the WT1 RNA content of single CD34 ϩ cells derived from the marrows of a series of normal donors, they demonstrated that, in fact, only 1 to 2% of the CD34 ϩ Lin Ϫ cells express any WT1 RNA at a given time and that, in this small fraction of cells, the level of WT1 was comparable with that detected in leukemic cells (46) . These findings are consistent with our findings that cytolysis is proportional to the fraction of cells expressing WT1 in the target population at the time of exposure to the WT1-peptide-specific T cells. The fact that WT1 protein can be detected in a small proportion of early CD34 ϩ hematopoietic progenitors has raised concerns regarding the potential myelosuppressive effects of WT1-specific T cells. In our studies, WT1-peptide-specific T cells neither lysed normal cord blood cells or CD34 ϩ cells nor inhibited the growth of CFU-GM, burst-forming unit erythroid, or mixed colonies from the isolated CD34 ϩ cells. Ohminami et al. (9) also demonstrated that TAK-1 did not inhibit the growth of CFU-GM from the marrow of normal HLA-A2401 ϩ donors. Similarly, the WT1-HLA-A0201-specific T-cell line developed by Gao et al. (11, 29) lysed WT1 ϩ CD34 ϩ chronic myelogenous leukemia cells, inhibited their colony-forming activity in vitro and prevented their growth in NOD-SCID mice but had no effect on normal HLA-A0201 ϩ CD34 ϩ cells (29) . In murine models, WT1 plasmid vaccines, inducing responses sufficient to prevent the growth of WT1 ϩ tumors, have also not affected normal hematopoietic function (47) . Similarly, in leukemic patients who achieve remissions and who have detectable antibody or T-cell responses to WT1, impaired recovery of blood counts has not been detected (26, 27) . These findings suggest that, either normal CD34 ϩ hematopoietic cells contain clonogenic progenitors in both WT1 ϩ and WT1 Ϫ fractions, or, as has been suggested by experiments with WT1 antisense oligonucleotides (48, 49), expression of specific isoforms of WT1 may be essential to the growth of clonogenic leukemic cells.
Although Gao et al. (29) have reported that preincubation of WT1
ϩ human leukemic blasts with T-cell lines can deplete clonogenic cells capable of transferring leukemia into NOD-SCID mice, the effects of WT1-peptide-specific T cells on established leukemic grafts have not heretofore been evaluated. Our studies demonstrate that after adoptive transfer into NOD-SCID mice that are bearing established leukemic xenografts, the WT1-peptide-specific T cells selectively infiltrate WT1 ϩ leukemias bearing the restricting HLA-allele and significantly inhibit their growth.
In ϩ and WT1 Ϫ leukemia xenografts, treated with EBV-TG-CTLs alone. However, in mice bearing the same group of tumors treated with HLA-A0201-restricted dual-specific WT1/EBV-TG-CTLs, the T cells also accumulated in the HLA-A0201 ϩ WT1 ϩ leukemia xenografts. In these animals, accumulations in the HLA-A0201 ϩ EBV-lymphomas were markedly higher then those in the HLA-A0201 ϩ WT1 ϩ leukemias, reflecting the 10-fold higher cumulative number of infused T cells specific for EBV peptides in the transduced T-cell population. Similarly, in the mice bearing leukemia and rhabdomyosarcoma xenografts that varied in the expression of WT1 or the HLA-A0201 restricting allele, WT1/EBV-TG-CTLs selectively accumulated only in tumors coexpressing WT1 and HLA-A0201.
Immunohistologic analysis of tumors from patients with several forms of cancer has documented the absence of HLAclass-I expression in a substantial proportion of cases (50) . Such tumors are resistant to cytotoxic T cells in vitro. Thus, modulation of HLA expression has been hypothesized to be a major mechanism whereby tumors can elude the immune system. In our studies, a WT1 ϩ rhabdomyosarcoma that failed to express its inherited HLA-A0201 allele and was resistant to lysis by WT1-peptide-specific HLA-A0201--restricted T cells in vitro also could not be targeted by the WT1-specific T cells in vivo (Fig. 5D) . Thus, tumors, or metastases thereof, that fail to express HLA-class-I in vivo may not only be resistant to lysis by specific T cells but may also be untargetable by such T cells in the circulation.
In conclusion, our studies demonstrate that T cells isolated from normal HLA-A0201 ϩ and HLA-A2402 ϩ individuals can be regularly sensitized with immunogenic peptides of the WT1 protein loaded on autologous APCs, and that the frequencies of
